Lung Heart Rate Variability

Withdrawn before enrolling · Not applicable

Conditions studied: Non Small Cell Lung Cancer

In brief

The purpose of this study is to examine the effects of heart-rate variability biofeedback training on lung cancer patients receiving definitive radiation therapy. The target population consists of non-small cell lung cancer (NSCLC) patients receiving 6 weeks of radiation therapy. The study will utilize the Physiolab GP8 heart rate variability and respiration system to collect data as well as several survey instruments to analyze quality of life measures. The goal is to show the HRV training can improve certain QOL measures like anxiety and sleep quality.

Key facts

Study ID

NCT03674450

Run by

Abramson Cancer Center at Penn Medicine

People needed

0

Starts

2019-01-02

Expected to finish

2019-04-11

Last updated by the study team

2020-04-07

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must be older than 18 years of age
• Both women and men of all ethnic background are eligible to participate in the study.
• Must be diagnosed with non-small cell lung cancer and receiving 6 weeks of radiation therapy.
• Must be available and willing to participate in 4, approximately 1 hour HRV biofeedback treatment sessions.
• Signed informed consent

You may not qualify if…

• Participant is younger than 18 or older than 70
• Diagnosed with early stage NSCLC
• Patients who are pregnant
• Patients with cardiac arrhythmias
• Patients with Pacemakers
• Patients taking beta-blockers
• Patients with any major mental illness, cognitive impairment
• Incapable of giving informed consent

Where it is running

• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.